Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations

BACKGROUND: Regimens that could treat both rifampin-resistant (RR) and rifampin-susceptible tuberculosis (TB) while shortening the treatment duration have reached late-stage clinical trials. Decisions about whether and how to implement such regimens will require an understanding of their likely clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendall, Emily A., Malhotra, Shelly, Cook-Scalise, Sarah, Denkinger, Claudia M., Dowdy, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734288/
https://www.ncbi.nlm.nih.gov/pubmed/31500572
http://dx.doi.org/10.1186/s12879-019-4429-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734288/
https://www.ncbi.nlm.nih.gov/pubmed/31500572
http://dx.doi.org/10.1186/s12879-019-4429-x

Ejemplares similares